Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,817,028

« Back to Dashboard

Summary for Patent: 5,817,028

Title: Method and device for the provocation of air passage narrowing and/or the induction of sputum
Abstract:A method as described for testing the susceptibility of a person to asthma. The person inhales an effective amount of sodium chloride, mannitol or another substance capable of altering the osmolarity of airway surface liquid in the subject. The substance is in the form of a dispersible dry powder containing an effective proportion of particles of a respirable size. The subject is then measured to detect airway narrowing which is indicative of a propensity for asthma. The same technique of dry powder inhalation can be used to test for the susceptibility of a person to rhinitus, to induce sputum and promote mucociliary clearance.
Inventor(s): Anderson; Sandra Doreen (Birchgrove, AU)
Assignee: Central Sydney Area Health Service (Camperdown, AU)
Application Number:08/696,987
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 17th percentile
Forward Citations: 4th percentile

No matches for this query

Foreign Priority and PCT Information for Patent: 5,817,028

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPM4114Feb 25, 1994
PCT Information
PCT FiledFebruary 23, 1995PCT Application Number:PCT/AU95/00086
PCT Publication Date:August 31, 1995PCT Publication Number: WO95/22993

International Patent Family for Patent: 5,817,028

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria474583► subscribe
Australia1748295► subscribe
Australia682756► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.